AstraZeneca (AZN, Financial), in collaboration with Daiichi Sankyo, has announced promising interim results from the phase 3 DESTINY-Breast09 trial involving Enhertu. In this study, Enhertu, when combined with pertuzumab, significantly extended progression-free survival in patients with HER2 positive metastatic breast cancer compared to the standard regimen of taxane, trastuzumab, and pertuzumab.
Enhertu, also known as a DXd antibody drug conjugate, demonstrated its effectiveness across all examined patient groups in this trial phase. While the trial primarily focused on progression-free survival (PFS), the secondary endpoint of overall survival (OS) remains under evaluation. Early indications suggest a favorable trend in OS for patients treated with Enhertu in combination with pertuzumab.
The ongoing study continues to assess the second component, which involves Enhertu in monotherapy versus the standard combination, with this part of the trial remaining blinded. Safety assessments reveal that the side effects associated with the Enhertu and pertuzumab combination align with those observed for the individual treatments.
These results bolster AstraZeneca and Daiichi Sankyo's confidence in Enhertu's potential to improve outcomes for those battling this challenging form of breast cancer, marking a significant step forward in first-line treatment options.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for AstraZeneca PLC (AZN, Financial) is $100.29 with a high estimate of $230.38 and a low estimate of $67.00. The average target implies an upside of 48.38% from the current price of $67.59. More detailed estimate data can be found on the AstraZeneca PLC (AZN) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, AstraZeneca PLC's (AZN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AstraZeneca PLC (AZN, Financial) in one year is $87.34, suggesting a upside of 29.22% from the current price of $67.59. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AstraZeneca PLC (AZN) Summary page.
